The Supreme Court appears unlikely to restrict access to mifepristone, a medication used in over 60% of U.S. abortions, challenging the lawsuit brought by antiabortion doctors against the government's regulation loosening. The justices, showing skepticism across ideological lines, focused on the legal standing of the challengers. The drug's safety, supported by multiple studies, was emphasized, alongside the 2016 and 2021 rule changes that facilitated its access.